Table 2 Budget impact analysis results.

From: Cost-utility and budget impact analysis of desmopressin for treating monosymptomatic nocturnal enuresis in Thai children

Parameters

No Treatment

Imipramine

Desmopressin Acetate

Total Cost (USD)

127.70

177.43

740.54

QALYs

9.5082

9.5122

9.7651

ICER (USD/QALY gained)

Reference

Reference

2,385.37* and 2,226.17**

  1. The table presents the primary outcomes of the cost-utility analysis, showing the total costs, total Quality-Adjusted Life Years (QALYs), and the Incremental Cost-Effectiveness Ratio (ICER) for each treatment strategy over a 13-year time horizon. Costs are reported in 2024 U.S. dollars. The ICER values for desmopressin acetate are calculated against two comparators.
  2. *Compared to no treatment.
  3. **Compared to imipramine.
Back to article page